YOLFTbeta
Joinn Laboratories(China)Co

Joinn Laboratories(China)Co

603127 · SHG · Healthcare / Diagnostics & Research

43.29CNY-2.87 (-6.22%)

Price History

Full chart

Market Stats

Previous Close46.16
Open45.97
Day Range43.04 – 46.22
52-Week Range26.25 – 55.68
Volume29.37M
Market Cap36.94B
P/E (TTM)37.35
Forward P/E36.10
EPS1.32
Dividend Yield0.24%
Beta0.83
50-Day Avg46.59
200-Day Avg39.51

About

Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics DMPK studies, and pharmacology and efficacy studies. Its Clinical Trial and Related Services segment provide clinical contract research organization services, co-managed phase I clinical research units, and bioanalytical services. The Sales of Research Models segment engages in the design, production, breeding, and sale of research models, including non-human primates and rodents. The company also offers cell-based assay (CBA) services. In addition, it offers drug quality research and testing services for protein drugs, vaccines, gene and cell therapy products, and provides customized solutions for early-stage drug discovery, screening, and mechanism research. Joinn Laboratories(China)Co.,Ltd. was incorporated in 1995 and is headquartered in Beijing, China.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEODr. Yuxia Feng M.D.
  • Employees2.50K
  • HeadquartersA5 Rongjing East Street, Beijing, China, 100176, China
  • Websitehttps://www.joinnlabs.com

Leadership

  • Dr. Yuxia Feng M.D.Founder & Chairman · b. 1964
  • Mr. Dapeng GaoGM, Secretary to the Board, Joint Company Secretary & Executive Director · b. 1982
  • Ms. Aishui YuChief Financial Officer · b. 1976
  • Mr. Jingliang GuVice GM, Head of Sales Department and Executive Director · b. 1980
  • Dr. Yunxia Sun DCBT, M.D.Vice GM & Executive Director · b. 1968
  • Ms. Xi LuoExecutive Director · b. 1978
  • Dr. Dalin YaoChief Scientific Officer · b. 1949
  • Ms. Ying Ching LeeJoint Company Secretary

Financials

Income Statement

Currency: CNY2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue97.39M143.83M184.81M206.61M241.81M301.28M408.80M639.38M1.08B1.52B2.27B2.38B2.02B1.66B
Growth (%)-+47.68%+28.50%+11.79%+17.04%+24.60%+35.69%+56.40%+68.27%+40.97%+49.54%+4.78%-15.07%-17.87%
Cost of Revenue49.82M71.29M86.58M100.17M119.79M131.92M192.38M310.28M524.60M778.89M1.19B1.39B1.50B1.31B
Gross Profit47.56M72.54M98.23M106.44M122.01M169.36M216.42M329.10M551.30M737.79M1.08B981.55M520.82M343.31M
Gross Margin48.84%50.43%53.15%51.52%50.46%56.21%52.94%51.47%51.24%48.65%47.68%41.30%25.80%20.71%
Operating Expense40.90M53.68M51.90M59.45M68.47M75.18M90.41M113.39M190.18M94.90M-164.85M474.46M416.47M385.44M
Operating Income6.67M18.86M46.33M46.99M53.55M94.18M126.01M215.71M361.12M642.89M1.25B507.10M104.35M-42.12M
Operating Margin6.84%13.11%25.07%22.74%22.14%31.26%30.82%33.74%33.56%42.39%54.95%21.34%5.17%-2.54%
EBITDA19.39M40.49M70.79M71.74M79.87M107.77M133.58M214.99M341.85M490.27M802.60M676.51M179.58M483.24M
EBITDA Margin19.91%28.15%38.30%34.72%33.03%35.77%32.68%33.63%31.77%32.32%35.39%28.47%8.90%29.15%
Net Income9.63M22.29M49.00M49.17M51.69M76.45M108.34M186.77M315.01M557.46M1.07B396.99M74.08M297.84M
Net Income Margin9.88%15.50%26.51%23.80%21.38%25.37%26.50%29.21%29.28%36.76%47.37%16.71%3.67%17.97%
R&D11.95M14.63M10.50M10.49M13.83M25.58M23.69M39.63M50.66M47.76M77.98M96.85M92.96M87.43M
R&D as % of Total Revenue12.27%10.17%5.68%5.08%5.72%8.49%5.79%6.20%4.71%3.15%3.44%4.08%4.61%5.27%
Interest Expense05.64M3.83M1.26M62.74K93.77K89.67K183.18K1.18M3.96M3.95M3.53M325.68K1.42M
Interest Expense % of Total Revenue0.00%3.92%2.07%0.61%0.03%0.03%0.02%0.03%0.11%0.26%0.17%0.15%0.02%0.09%

Balance Sheet

Currency: CNY2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets380.06M380.10M451.71M481.99M597.06M940.87M1.14B1.42B2.11B8.54B10.36B10.03B9.40B9.68B
Total Liabilities280.79M258.21M292.63M273.64M336.88M383.08M489.89M590.57M883.66M1.39B2.17B1.75B1.32B1.36B
Total Equity99.27M121.54M158.72M208.00M259.83M557.44M651.32M826.52M1.22B7.14B8.18B8.28B8.08B8.32B
Cash41.13M26.15M50.88M63.26M132.70M404.62M148.69M176.96M308.69M4.15B2.92B2.86B965.20M911.85M
Total Debt118.10M63.00M49.00M---9.50M22.32M24.46M95.32M87.71M41.92M60.97M-
Net Debt76.97M36.85M-1.88M-63.26M-132.70M-404.62M-139.20M-154.63M-284.23M-4.06B-2.83B-2.82B-904.23M-

Cash Flow

Currency: CNY2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow20.33M60.91M82.38M106.23M118.82M120.01M176.08M148.09M428.39M685.66M971.07M647.73M338.93M444.57M
Investing Cash Flow-58.11M-17.79M-42.47M-44.52M-52.42M-223.67M-269.53M-102.09M-254.90M-2.07B-2.16B-340.28M-1.96B-
Financing Cash Flow28.06M-57.61M-15.10M-49.51M2.33M227.13M-15.29M-15.41M-36.87M5.29B-99.33M-361.68M-265.63M-
Capital Expenditure57.77M52.26M38.89M43.21M52.42M25.32M129.92M126.78M148.98M237.24M274.84M192.72M269.39M143.60M
Free Cash Flow-37.44M8.65M43.49M63.02M66.40M94.69M46.15M21.32M279.41M448.41M696.23M430.15M69.54M300.96M
Dividends Paid8.74M5.89M13.64M3.60M8.91K20.63K24.64M34.49M55.05M94.85M137.36M214.24M119.63M22.39M
FCF to OCF-184.12%14.20%52.79%59.33%55.88%78.90%26.21%14.39%65.22%65.40%71.70%66.41%20.52%67.70%
Dividend Paid to FCF-23.36%68.06%31.37%5.71%0.01%0.02%53.39%161.80%19.70%21.15%19.73%49.81%172.04%7.44%

Earnings

Report DateOct 25, 2017Feb 27, 2018Apr 28, 2018Aug 29, 2018Oct 29, 2018Mar 1, 2019Apr 29, 2019Aug 12, 2019Oct 30, 2019Mar 24, 2020Apr 12, 2020Aug 30, 2020Oct 30, 2020Mar 29, 2021Apr 30, 2021Aug 30, 2021Oct 29, 2021Feb 24, 2022Apr 28, 2022Aug 30, 2022Oct 28, 2022Mar 30, 2023Apr 27, 2023Aug 30, 2023Oct 30, 2023Mar 28, 2024Apr 29, 2024Jun 30, 2024Oct 30, 2024Mar 28, 2025Apr 28, 2025Aug 26, 2025Sep 30, 2025Mar 30, 2026Mar 31, 2026Aug 28, 2026
EPS Estimate-------------0.36----0.360.360.300.420.340.120.240.040.100.190.150.180.110.210.130.300.060.48
EPS Actual0.100.190.040.060.150.230.050.120.160.320.320.130.100.440.350.161.020.640.240.440.350.560.35-0.080.320.09-0.370.130.110.190.030.030.030.290.320.68
Surprise-------------22.22%-----33.33%22.22%16.67%33.33%2.94%-166.67%33.33%125.00%-470.00%-31.58%-26.67%5.56%-72.73%-85.71%-77.12%-3.33%433.33%41.67%
TimingPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-market-Pre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-market-Pre-marketPre-marketPre-marketPre-market-Pre-market-After-hours

Key Statistics & Ratios

Market Cap36.94B
Enterprise Value30.56B
Trailing P/E37.35
Forward P/E36.10
Price / Sales21.82
Price / Book3.99
EPS1.32
Book Value11.96
Revenue (TTM)1.69B
Gross Profit (TTM)323.46M
EBITDA-17.98M
Profit Margin58.15%
Operating Margin-7.00%
Return on Equity11.53%
Return on Assets-0.74%
Shares Outstanding630.35M
Shares Float494.39M
Beta0.83
Dividend Yield0.24%
Dividend Rate0.12
Payout Ratio11.36%

Dividends

20231×
0.40Jul 25, 2023
20221×
0.26Aug 8, 2022
20211×
0.18Aug 5, 2021
20201×
0.12Jun 8, 2020
20191×
0.08Apr 10, 2019
20181×
0.06May 31, 2018

Stock Splits

  • Jul 25, 20237:5
  • Aug 8, 2022188394:134567
  • Aug 5, 20217:5
  • Jun 8, 20207:5
  • Apr 10, 20197:5
  • May 31, 20187:5